Posted by Michael Wonder on 02 Nov 2022
FDA approves oral MEK inhibitor cobimetinib for histiocytic neoplasms, research led by Memorial Sloan Kettering Cancer Center
1 November 2022 - Memorial Sloan Kettering Cancer Center announced today that the US FDA has approved the oral MEK inhibitor drug cobimetinib (Cotellic) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms.
These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis.
